University of Virginia Health System
Charlottesville, Virginia, 22908, United States
NCT Number: NCT03968211
This study is trying to find out if an undetectable serum immunoglobulin E (IgE) is a biomarker, or early sign of, the development of immune deficiency.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 1
Charlottesville, Virginia, 22908, United States
IgE is the antibody thought to be responsible for developing allergies. Undetectable serum IgE (an IgE below the lower limit of detection) is found in about 3% of the general population. In the past, it has been thought that having an undetectable IgE does not have any health impact, other than meaning that you are at low risk for having allergies. However, recent studies of patients with undetectable IgE have shown higher rates of infections, autoimmune disease and cancer.
Patients with an immune deficiency called common variable immunodeficiency (CVID) also have higher rates of infections, autoimmune disease and cancer. Recently, we have shown that most patients with CVID have a low/undetectable serum IgE.
This study is trying to find out if an undetectable serum IgE is a biomarker, or early sign of, the development of CVID or other antibody deficiencies
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Salmonella typhi polysaccharide vaccine
Other names: Typhim Vi
Time frame: 4-6 weeks
IgG to Salmonella typhi will be measured, with a normal response calculated as at least a 2-fold increase in IgG titers post-vaccination
Time frame: 3 days
B cells isolated from subjects will be evaluated to determine their ability to produce Epsilon germline transcript in response to stimulation
University of Virginia
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00852943
Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Bethesda, Maryland, United States
View Trial DetailsNCT04818177
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Somerville, New Jersey, United States
View Trial DetailsNCT06089174
Immune Deficiency, Immune System Diseases
Saint-Denis, Reunion
View Trial DetailsNCT04979065
Avitaminosis, Body Weight
Jakarta, DKI Jakarta, Indonesia
View Trial Details